S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NYSE:USNA

USANA Health Sciences Stock Forecast, Price & News

$89.56
+2.89 (+3.33 %)
(As of 01/25/2021 05:06 PM ET)
Add
Compare
Today's Range
$86.51
Now: $89.56
$89.60
50-Day Range
$75.28
MA: $78.66
$85.63
52-Week Range
$43.01
Now: $89.56
$92.26
Volume147,657 shs
Average Volume83,204 shs
Market Capitalization$1.88 billion
P/E Ratio16.59
Dividend YieldN/A
Beta0.98
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
USANA Health Sciences logo

MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

145th out of 1,922 stocks

Medicinals & Botanicals Industry

1st out of 33 stocks

Analyst Opinion: 2.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryPersonal Products
SectorMedical
CUSIP90328M10
Phone801-954-7100
Employees1,909
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.06 billion
Cash Flow$6.48 per share
Book Value$16.25 per share

Profitability

Net Income$100.53 million

Miscellaneous

Market Cap$1.88 billion
Next Earnings Date2/9/2021 (Confirmed)
OptionableOptionable
$89.56
+2.89 (+3.33 %)
(As of 01/25/2021 05:06 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

How has USANA Health Sciences' stock been impacted by COVID-19?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, USNA stock has increased by 27.9% and is now trading at $89.40.
View which stocks have been most impacted by COVID-19
.

Is USANA Health Sciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than USANA Health Sciences?

Wall Street analysts have given USANA Health Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but USANA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for USANA Health Sciences
.

How can I listen to USANA Health Sciences' earnings call?

USANA Health Sciences will be holding an earnings conference call on Tuesday, February 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings data on Tuesday, October, 20th. The company reported $1.44 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.15. The company had revenue of $298.50 million for the quarter, compared to analysts' expectations of $281.80 million. USANA Health Sciences had a trailing twelve-month return on equity of 32.91% and a net margin of 10.57%. The business's revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 earnings per share.
View USANA Health Sciences' earnings history
.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its board has initiated a stock buyback program on Wednesday, February 5th 2020, which permits the company to buyback $130,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 9.1% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its shares are undervalued.

What price target have analysts set for USNA?

2 brokerages have issued 1 year target prices for USANA Health Sciences' stock. Their forecasts range from $107.00 to $107.00. On average, they expect USANA Health Sciences' share price to reach $107.00 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for USANA Health Sciences
or view Wall Street analyst' top-rated stocks.

Who are some of USANA Health Sciences' key competitors?

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:
  • Mr. Kevin G. Guest, Chairman & CEO (Age 58, Pay $1.39M)
  • Mr. Jim Brown, Pres (Age 52, Pay $905.81k)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 51, Pay $641.25k)
  • Dr. Myron W. Wentz, Founder & Chairman Emeritus (Age 80)
  • Dr. John Cuomo, Exec. Director of Product Devel. & Technology
  • Mr. Patrique Richards, Exec. Director of Investor Relations & Bus. Devel.
  • Ms. Ashley Collins, VP of Marketing & PR
  • Ng Keng Hean, Exec. VP of South Asia
  • Mr. Sherman Ying, Exec. VP of North Asia
  • Dr. Brian Dixon, Exec. Director of Health & Science Education

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Strs Ohio (0.05%), State of Alaska Department of Revenue (0.04%) and Pacer Advisors Inc. (0.03%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences
.

Which major investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences
or view top insider-selling stocks.

Which major investors are buying USANA Health Sciences stock?

USNA stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., and Strs Ohio.
View insider buying and selling activity for USANA Health Sciences
or or view top insider-buying stocks.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $89.40.

How big of a company is USANA Health Sciences?

USANA Health Sciences has a market capitalization of $1.88 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis. USANA Health Sciences employs 1,909 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.